Obesity or Overweight study: Lenbelintide
Official title A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
ClinicalTrials.gov ID: NCT07784725
What this study is testing
What is Lenbelintide?
An investigational once‑weekly injectable medicine being studied as a potential treatment for obesity or overweight.
Also referred to as AZD6234.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether AZD6234 helps adults lose weight and is safe to use.
- Who it's for
- You may be able to join if you are an adult with obesity or overweight and do not have type 2 diabetes.
- What's involved
- You would take AZD6234 pills or a pretend pill for about 68 weeks. You will have regular check‑ins to measure your weight.
- Time commitment
- The study lasts about 68 weeks with periodic clinic visits.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Males \& females (inclusive of all gender identities) age ≥18 years
- BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia...
- Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
- History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime
You likely can't join if
- Obesity primarily caused by other endocrine disorders
- History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to...
- ALT ≥ 3.0 × ULN
- AST ≥ 3.0 × ULN
- TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome)
- Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.
The study team makes the final eligibility decision.
Where it is enrolling
- Dothan, Alabama, United States
- Escondido, California, United States
- Clearwater, Florida, United States
- Stockbridge, Georgia, United States
- Champaign, Illinois, United States
- Chicago, Illinois, United States
- Ames, Iowa, United States
- Kansas City, Missouri, United States
- Rocky Mount, North Carolina, United States
- Statesville, North Carolina, United States
- Fargo, North Dakota, United States
- Columbus, Ohio, United States
- Tulsa, Oklahoma, United States
- Philadelphia, Pennsylvania, United States
- Smithfield, Pennsylvania, United States
- Kingsport, Tennessee, United States
- Houston, Texas, United States
- Sugar Land, Texas, United States
- Waco, Texas, United States
- Buenos Aires, Argentina
+ 50 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Dothan, Alabama, United States; Escondido, California, United States; Clearwater, Florida, United States; Stockbridge, Georgia, United States; Champaign, Illinois, United States; Chicago, Illinois, United States and 64 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.